Biohaven Ltd.
NYSE:BHVNBiotechnology
-$0.22 today
- Market cap
- $1.95B
- Beta
- 3.31
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$4.39
Volume 2.32M
Average 2.47M
BHVN Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Biohaven Ltd.NYSE: BHVN
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q2 FY2026 depreciation & amortization of $2.26M rose 14.2% year over year, behind the +18.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 4.5% from the prior quarter. Over 3 fiscal years it compounded at +92.7% a year.
Context
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +14.2% toward the trailing-twelve-month pace of +18.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 9.92M USD
- Year-over-year change
- +26.3%
- 4-year CAGR
- +63.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.92M | +26.3% |
| FY2024 | 2024-12-31 | 7.86M | +13.6% |
| FY2023 | 2023-12-31 | 6.91M | +398.7% |
| FY2022 | 2022-12-31 | 1.39M | -0.5% |
| FY2021 | 2021-12-31 | 1.39M | — |
Depreciation & Amortization vs competitors
How BHVN compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +18.9% is the 5th highest of 11, against a peer median of +6.7%.
- Over three fiscal years its annual growth of +92.7% compares with a peer median of +5.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $32.16M USD | -7.6% | -4.5% | 47.4% | |
| LTM Mar 2026 | $12.47M USD | +3.0% | -1.4% | 4.0% | |
| LTM Jun 2026 | $10.32M USD | +18.9% | +92.7% | — | |
| LTM Mar 2026 | $9.99M USD | -2.7% | +10.7% | 15.1% | |
| LTM Sep 2026 | $3.76M USD | +35.4% | +67.3% | — | |
| LTM Sep 2026 | $3.73M USD | +10.4% | +5.3% | 3333.9% | |
| LTM Mar 2026 | $3.36M USD | -17.0% | -23.1% | 0.9% | |
| LTM Mar 2026 | $1.05M USD | -922.8% | — | — | |
| LTM Mar 2026 | $904K USD | +36.8% | — | — | |
| LTM Jun 2026 | $652K USD | +130.4% | — | — | |
| LTM Sep 2026 | €483K EUR | +19.4% | +39.9% | — | |
| Peer median (excluding BHVN) | — | +6.7% | +5.3% | 15.1% | |
Competitors are the stored peer set for BHVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (213.8M) | (570.28M) | (408.17M) | (846.42M) | (738.82M) |
| Depreciation & Amortization | 1.39M | 1.39M | 6.91M | 7.86M | 9.92M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 65.64M | 193.56M | 28.79M | 71.96M | 112.36M |
| Change in Working Capital | 1.66M | (28.6M) | 24.61M | 16.81M | 1.36M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.03M | 5.93M | 4.87M | 710K | (6.39M) |
| Other Working Capital | 639K | (34.53M) | 19.74M | 16.1M | 7.74M |
| Other Non-Cash Items | (740K) | 106.25M | 16.13M | 167.34M | 5.74M |
| Operating Cash Flow | (145.84M) | (297.69M) | (331.73M) | (582.45M) | (609.44M) |
| Capital Expenditures | (938K) | (41.07M) | (3.05M) | (4.05M) | (715K) |
| Acquisitions (Net) | 1.88M | 0 | 0 | 391K | 0 |
| Purchases of Investments | 0 | (263.72M) | (194.12M) | (745.68M) | (266.88M) |
| Sales of Investments | 0 | 0 | 327M | 504.36M | 570M |
| Other Investing Activities | 0 | 0 | 0 | 0 | (1.85M) |
| Investing Cash Flow | 944K | (304.79M) | 129.83M | (244.97M) | 300.56M |
| Debt Repayment | 0 | 449.13M | 0 | 0 | 250M |
| Common Stock Issued | 0 | 283.8M | 243.23M | 675.52M | 189.31M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 138.45M | 34.66M | (31.32M) | 2.26M | (194K) |
| Financing Cash Flow | 138.45M | 767.6M | 211.91M | 677.77M | 439.12M |
| Effect of Forex Changes | 0 | 429K | (497K) | 75K | (3K) |
| Net Change in Cash | (6.45M) | 165.55M | 9.52M | (149.58M) | 130.24M |
| Free Cash Flow | (146.78M) | (338.76M) | (334.77M) | (586.5M) | (610.15M) |
Biohaven Ltd.
NYSE:BHVN
Intrinsic Alpha fair value
Locked
Current Price
$12.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.